Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Net Income (2016 - 2025)

Cytokinetics (CYTK) has disclosed Net Income for 16 consecutive years, with -$231.9 million as the latest value for Q4 2025.

  • Quarterly Net Income changed N/A to -$231.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$688.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$657.8 million for FY2025, 14.62% down from the prior year.
  • Net Income for Q4 2025 was -$231.9 million at Cytokinetics, down from -$178.1 million in the prior quarter.
  • The five-year high for Net Income was -$13.7 million in Q2 2022, with the low at -$231.9 million in Q4 2025.
  • Average Net Income over 5 years is -$115.0 million, with a median of -$129.4 million recorded in 2023.
  • The sharpest move saw Net Income tumbled 6173.01% in 2021, then soared 76.76% in 2022.
  • Over 5 years, Net Income stood at -$25.9 million in 2021, then tumbled by 417.27% to -$134.1 million in 2022, then decreased by 0.37% to -$134.6 million in 2023, then dropped by 11.25% to -$149.7 million in 2024, then crashed by 54.86% to -$231.9 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$231.9 million, -$178.1 million, and -$122.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.